SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Otros idiomas Shanghai Shyndec Pharmaceutical Co., Ltd.

Acciones

600420

CNE000001JG2

Precio de cierre Shanghai S.E. Otros sitios de cotización 00:00:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
10,88 ^CNY	+2,93 %		+3,42 %	+11,13 %

29/04	Shanghai Shyndec Pharmaceutical Co., Ltd. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
15/04	Las acciones chinas suben tras las nuevas directrices; las de Hong Kong caen	RE

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	16/04
China stocks rise after new guidelines; HK shares drop	15/04
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	10/04
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	27/03
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine	07/03
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	21/02
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	20/02
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/01
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	03/01
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets	08/12
Shyndec Pharma Passes Drug GMP Compliance Inspection	28/11
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid	08/11
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation	07/11
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing	19/09/23
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index	18/09/23
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient	14/09/23
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/07/23
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection	06/07/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Shanghai Shyndec Pharmaceutical Co., Ltd.

Acciones

600420

CNE000001JG2

Otros idiomas

Filtros